With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World's First Known 200,000+ Standardized EEG/ERP Depository
MWN-AI** Summary
Firefly Neuroscience, Inc. has made headlines by achieving a significant milestone in the field of brain health with the completion of over 200,000 standardized EEG/ERP brain scans. This accomplishment comes on the heels of steady growth in brain scan volumes, registering sequential increases of 5%, 11%, 15%, and 17% over the last four quarters. By acquiring Evoke Neuroscience in May 2025 and leveraging advanced NVIDIA L40S GPU acceleration, Firefly is positioned to enhance its EEG/ERP processing capabilities, paving the way for innovative AI-driven biomarker discoveries.
Firefly's CEO, Greg Lipschitz, emphasized that surpassing this milestone opens extensive opportunities for breakthroughs in cognitive brain biomarker discovery. The company aims to advance diagnostic precision in conditions like ADHD, Alzheimer’s-related cognitive issues, and more, with the ultimate goal of creating and launching the world’s first EEG/ERP-based foundation model of the human brain.
Operating within the NASDAQ under the ticker AIFF, Firefly is focused on utilizing AI and large-scale electrophysiological data to provide a deeper, objective understanding of individual brain function. Their proprietary database has become the largest known standardized EEG/ERP repository globally, which may revolutionize diagnostic and monitoring methods for various neurological and mental health disorders, including depression and anxiety.
Despite the optimism surrounding Firefly’s progress, forward-looking statements in their press release highlight inherent risks and uncertainties that could affect future outcomes. The company does not guarantee that anticipated developments will occur and will continually assess various factors that might influence its trajectory. For more information, visit www.fireflyneuro.com.
MWN-AI** Analysis
Firefly Neuroscience, Inc. (NASDAQ: AIFF) has achieved a significant milestone by surpassing 200,000 standardized EEG/ERP brain scans, positioning itself as a leader in the field of neuroscience. This impressive feat, achieved through innovative growth initiatives and the acquisition of Evoke Neuroscience, showcases sequential brain scan volume increases of 5%, 11%, 15%, and 17% over the past four quarters, signaling strong operational momentum.
The ramp-up in scan volumes, powered by the utilization of advanced NVIDIA L40S GPU acceleration, enhances Firefly's capabilities in AI-driven biomarker discovery. This technology enables the company to potentially unlock new diagnostic pathways for neurological and mental disorders, including ADHD, depression, and dementia. With clinical applications that are being recognized and validated through FDA clearance of its brain analytics technology, Firefly and its proprietary database stand on the brink of transforming care models in cognitive health.
From an investment perspective, Firefly exhibits strong growth potential. The ongoing expansion and increased utilization of its EEG/ERP repository could lead to valuable partnerships and higher demand for its AI-driven solutions. Investors should consider the firm's innovative approach and the evolving landscape of precision neuroscience as key drivers for future profitability.
However, potential investors must also tread carefully. The company faces typical biotech risks, including dependence on regulatory approvals and market acceptance of its technology. Furthermore, execution risks surrounding its ambitious plans to build an EEG/ERP-based foundation model of the human brain could impact financial performance.
Overall, Firefly represents an exciting opportunity within the AI healthcare sector; however, prospective investors should remain vigilant of the inherent risks and uncertainties associated with emerging technologies in the medical field. Diversifying exposure while closely monitoring Firefly’s advancements would be a prudent strategy in navigating this promising yet volatile market landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Firefly’s total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters -
- Firefly is harnessing increased data and NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, enabling new AI-driven biomarker discovery capabilities –
- Milestone supports Firefly’s goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain -
KENMORE, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce the achievement of a major operational and commercial milestone: over 200,000 EEG/ERP (human brain function) scans.
Through its acquisition of Evoke Neuroscience, Inc. in May 2025, combined with the successful execution of its key internal growth initiatives, Firefly has now driven 5%, 11%, 15%, and 17% sequential EEG/ERP brain scan volume growth, respectively, over the past four quarters.
“Surpassing this important milestone opens the door to us potentially making additional new breakthroughs in cognitive brain biomarker discovery, building upon those we’ve already recently made for differential diagnosis of ADHD, objective measurement of SCD/MCI/Dementia in Alzheimer's patients, and cognitive assessment of brain age,” commented Firefly’s Chief Executive Officer, Greg Lipschitz. “In so doing, we also believe we are now much closer to fulfilling our goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
About Firefly
Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. Firefly’s proprietary database now consists of over 200,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
FAQ**
How does Firefly Neuroscience Inc. AIFF plan to leverage its proprietary database of over 200,000 EEG/ERP brain scans to enhance its AI-driven biomarker discovery capabilities for neurological disorders?
What specific milestones does Firefly Neuroscience Inc. AIFF aim to achieve in building and launching the world's first EEG/ERP-based foundation model of the human brain?
In light of Firefly Neuroscience Inc. AIFF's recent quarterly growth percentages, what strategies are being employed to sustain this momentum in EEG/ERP scan volume increases?
How does the acquisition of Evoke Neuroscience, Inc. strengthen Firefly Neuroscience Inc. AIFF’s position in the market for AI-driven neurological health solutions and improve patient outcomes?
**MWN-AI FAQ is based on asking OpenAI questions about Firefly Neuroscience Inc. (NASDAQ: AIFF).
NASDAQ: AIFF
AIFF Trading
-6.21% G/L:
$1.585 Last:
173,654 Volume:
$1.72 Open:
